Last reviewed · How we verify
NCT06672913: TR-SSCinNICU
Impact of Standardized Skin-to-Skin Care on Clinical Outcomes in Infants Born ≤ 32 Weeks: A Multicenter Study
NA trial testing skin to skin contact care in Premature in 120 participants. Currently enrolling.
1 April 2025
Quick facts
| Lead sponsor | Baskent University Ankara Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 120 |
| Start date | 1 September 2024 |
| Primary completion | 1 April 2025 |
| Estimated completion | 1 June 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- skin to skin contact care
Conditions studied
- Premature — all drugs for Premature →
- Skin to Skin Contact — all drugs for Skin to Skin Contact →
- Breast Feeding — all drugs for Breast Feeding →
- Necrotizing Enterocolitis — all drugs for Necrotizing Enterocolitis →
Sponsor
Baskent University Ankara Hospital
Who can join
1 Day and older, any sex, with Premature or Skin to Skin Contact. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multi-center, prospective pre-post clinical study conducted under the leadership of the Turkish Neonatal Society. It aims to investigate the effects of a standardized skin-to-skin care in NICU, initiated early and applied regularly, on recieving exclusive mothers' milk at discharge and clinical outcomes for preterm infants born ≤ 32 weeks of gestation. 1. Primary Objective: To evaluate the rate of receiving exclusive mothers' milk at discharge for infants born ≤ 32 weeks of gestation who have received skin-to-skin care in accordance with the study protocol. 2. Secondary Objective: To evaluate the rates of neonatal sepsis, intraventricular hemorrhage, and necrotizing enterocolitis (stage 2 and above) as well as the length of hospital stay for infants born at or below 32 weeks of gestation who have received skin-to-skin care in accordance with the study protocol.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06672913
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Premature
Currently open trials in the same condition.
- NCT07371845 — Effect of Teach-Back Education on Breastfeeding and Bonding in Mothers of Preterm Infants · NA · recruiting
- NCT07049900 — Baby ABS (Abdominal Binder Study) · NA · recruiting
- NCT07154186 — Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients · recruiting
- NCT07088302 — Effect OF Lactase Enzyme Supplements ON Intolerance IN Preterm Neonates · NA · recruiting
- NCT06812507 — Evaluation of Placental Transfusion Techniques in Prevention of Prematurity Related Complications and Effect on Their He · NA · recruiting
Other Baskent University Ankara Hospital trials
Trials by the same sponsor.
- NCT06265363 — Evaluation of the Frequency, Risk Factors, and Outcomes of ROP in Infants With a BW >1500 Grs or GA ≥33 Wks in Turkey. · recruiting
- NCT06466915 — Propofol vs. Nasal Dexmedetomidine in Pediatric Agitation and Delirium · Phase 4 · completed
- NCT06403670 — Dexmedetomidine and Remifentanil in NORA · Phase 4 · completed
- NCT05474625 — Efficacy of High-intensity Laser Therapy (HILT) in the Patients With Cervical Disc Herniation · NA · completed
- NCT05505032 — Oxygen Reserve Index and Prevention of Hyperoxemia · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06672913 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baskent University Ankara Hospital
- Last refreshed: 4 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06672913.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing